Fmr LLC Grifols Sa Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Grifols Sa stock. As of the latest transaction made, Fmr LLC holds 31,720 shares of GRFS stock, worth $301,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,720

Previous 16,532 91.87%

Holding current value

$301,340

Previous $110,000 80.91%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$6.27 - $7.7 $95,228 - $116,947	15,188 Added 91.87%	31,720 $199,000
Q1 2024 May 13, 2024	SELL	$5.47 - $11.38 $197,040 - $409,930	-36,022 Reduced 68.54%	16,532 $110,000
Q4 2023 Feb 13, 2024	BUY	$7.71 - $11.56 $56,460 - $84,653	7,323 Added 16.19%	52,554 $607,000
Q3 2023 Nov 13, 2023	BUY	$8.91 - $10.91 $2,494 - $3,054	280 Added 0.62%	45,231 $413,000
Q2 2023 Aug 11, 2023	SELL	$7.14 - $9.29 $443,593 - $577,169	-62,128 Reduced 58.02%	44,951 $411,000
Q1 2023 May 11, 2023	BUY	$6.65 - $10.69 $36,568 - $58,784	5,499 Added 5.41%	107,079 $789,000
Q4 2022 Feb 13, 2023	BUY	$5.96 - $8.53 $114,610 - $164,031	19,230 Added 23.35%	101,580 $863,000
Q3 2022 Nov 10, 2022	BUY	$5.95 - $14.3 $17,796 - $42,771	2,991 Added 3.77%	82,350 $507,000
Q2 2022 Aug 12, 2022	SELL	$10.6 - $13.28 $45,240 - $56,679	-4,268 Reduced 5.1%	79,359 $943,000
Q1 2022 May 13, 2022	BUY	$10.37 - $12.73 $292,672 - $359,278	28,223 Added 50.94%	83,627 $977,000
Q4 2021 Feb 14, 2022	SELL	$10.21 - $15.27 $724 - $1,084	-71 Reduced 0.13%	55,404 $622,000
Q3 2021 Nov 15, 2021	BUY	$14.07 - $17.3 $757,585 - $931,501	53,844 Added 3301.29%	55,475 $810,000
Q2 2021 Aug 13, 2021	BUY	$16.62 - $18.94 $27,107 - $30,891	1,631 New	1,631 $28,000

Others Institutions Holding GRFS

# of Institutions

151

Shares Held

151M

Call Options Held

2.37M

Put Options Held

638K

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $6.45B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account